| 摘要 |
<p>SUMMARY OF THE INVENTION The present invention provides an immunogenic target for administration to a patient to prevent and/or treat cancer. In particular, the immunogenic target is a CEA tumor antigen (" TA" ) and/or an angiogenesis-associated antigen (" AA" ). In one embodiment, the immungenic target is encoded by a modified CEA nucleotide sequence (CEA (6D) -1, 2) that improves CEA expression in transfected cells. In certain embodiments, the TA and/or AA are administered to a patient as a nucleic acid contained within a plasmid or other delivery vector, such as a recombinant virus. The TA and/or AA may also be administered in combination with an immune stimulator, such as a co-stimulatory molecule or adjuvant.</p> |
